Tumor-targeting properties of 90Y- and 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model

This publication has 25 references indexed in Scilit:

• Evaluation of the Human Melanoma Targeting Properties of Radiolabeled α-Melanocyte Stimulating Hormone Peptide Analogues
  Bioconjugate Chemistry, 2003
• In vivo evaluation of ¹⁸⁸Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy
  International Journal of Cancer, 2002
• Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
  Seminars in Nuclear Medicine, 2002
• [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy
  International Journal of Cancer, 2001
• Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
  European Journal of Nuclear Medicine and Molecular Imaging, 2001
• Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
  Current Medicinal Chemistry, 2000
• Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
  Proceedings of the National Academy of Sciences, 1998
• Yttrium-90-labelled somatostatin-analogue for cancer treatment
  The Lancet, 1998
• Radionuclide therapy revisited
  European Journal of Nuclear Medicine and Molecular Imaging, 1991
• Radionuclide diagnosis and therapy of thyroid cancer: Current status report
  Seminars in Nuclear Medicine, 1985